anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
NEW MATERIAL:The compound of formula I (R&lt;1&gt; and R&lt;2&gt; are lower alkyl; n is 0-2). EXAMPLE:2-[(1-methyl-1,2,3,4-tetrazol-5-yl)thio]acetic acid methyl ester. USE:A radiation sensitizer to increase the radiation sensitivity of intercalary hypoxic tumor cell of phyma. It has excellent transferability between tissues and solubility in water, high resistance to inactivation by metabolism, and low side effects. PREPARATION:The compound of formula I (sulfide derivative) wherein n is 0 can be produced by reacting the mercaptotetrazole derivative of formula II (M is H or alkali metal) with the acetic acid derivative of formula III in a solvent such as alcohol, ether, etc. at 10-60 deg.C. The obtained sulfide derivative is oxidized with 1-1.5 equivalent of oxidizing agent to obtain a sulfoxide derivative (n=1) or with 2-4 equivalent of oxidizing agent to afford a sulfone derivative (n=2).
The invention relates to an oral, nasal and throat bi-component spray with antibacterial and antiviral functions, which comprises a first component and a second component which are respectively packaged; the first component contains a cationic biological component, glycerol, sodium chloride, purified water and a pH regulator; the cationic biological component is one or more of water-soluble chitosan, gelatin and guar gum. The mass concentration of the cationic biological component in the first component is 0.1-2%. The second component comprises anionic biological component, glycerol, sodium chloride, purified water and pH regulator; the anionic biological component is one or more of alginate, sodium hyaluronate and polyglutamic acid. The concentration of the anionic biocomponent in the second component is 0.1-2%. The invention is used for preventing bacteria or virus from infecting upper respiratory tracts such as nasal cavities, oral cavities, throats and the like and protecting the health of human respiratory tracts. The invention can be used as a &#39;liquid mask&#39; which can quickly protect respiratory tract cells of a human body in a special period.
PURPOSE: To efficiently produce essence of medicinal ginseng having a high content of panaxan showing the effect of a medicine such as lowering action on blood sugar. CONSTITUTION: Ginseng itself or a cell lump obtained by its liquid culture is dried in the sun or by heating. The dried cell lump is fractioned as it is or ground by a grinder or a stone mill and fractioned by a sieve by particle diameters to give the granular or powdery cell lump having &lt;=1mm particle diameters. The cell lump is extracted with water to give essence of ginseng. The extracted amount of panaxan based on 1g solid content of the essence is &gt;=10mg. The ratio of the extracted amount of panaxan to that of saponin is &gt;=1.5. Consequently, the extracted amount of panaxan is increased in an extremely higher ratio than those of the solid content weight of the essence of ginseng and the extracted amount of saponin with 1mm particle diameter of the cell lump as a boundary to efficiently extract the essence of ginseng having a high content of panaxan showing lowering action on blood sugar.
Abstract of the Disclosure B-cell lymphomas express surface immunoglobulin (immunoglobulin) containing unique idiotypic (idiotype) determinants which may be exploited as tumor specific markers. Applicant has produced murine monoclonal antibodies (MAbs) reactive with the idiotype marker derived from 67 patients with low grade, follicular, small cleaved cell lymphoma. Out of 199 monoclonal antibodies, 47 (24%) were found to react with pooled normal human serum immunoglobulin in concentrations ranging from 0.6 µg/ml to 160 µg/ml. Of these 40 monoclonal antibodies, 90% cross-reacted with idiotype present in normal serum in levels &lt;50 µg/ml. Thirty-two of these anti-idiotypes were directed against a shared idiotope expressed on another patient&#39;s lymphoma cells. The frequency of shared idiotope expression defined by each antibody ranged from 0.26% to 3.9% of the B-cell lymphomas tested. A panel of five anti-idiotype antibodies reacted with 80% of AIDS associated lymphomas. Based on the reactivity with these monoclonal antibodies, tumors could be grouped into distinct families. In aggregate, these 32 monoclonal antibodies reacted with a total of 108 of 332 B cell lymphoma cases (32.5%), including 35 of 116 follicular, small cleaved cell lymphomas (30%). Many of these anti-shared idiotopes reacted with more than one histopathologic subtype of lymphoma Anti-idiotypes have been used in B-cell lymphoma diagnosis and therapy. Moreover, applicant has discovered at least seven anti-shared idiotype antibodies that cross react with autoantibodies, e.g., 16.6 and RF. The development of a library of anti-idiotypes reactive with shared idiotopes should facilitate these clinical studies by obviating the need to develop a customized hybridoma for each patient.
PURPOSE:To obtain the titled soft capsule resistant to the change of the enteric dissolution property with time, the degradation of the content, etc., by dissolving gelatin in an alkaline aqueous solution of a film-forming substance soluble in alkali and insoluble in acidic state, encapsulating a drug component with said solution, and treating the capsule with an acid after drying. CONSTITUTION:Gelatin is dissolved in an alkaline aqueous solution of a film- forming substance soluble in alkaline state and insoluble at &lt;=5 pH (e.g., alpha,beta- ethylenic unsaturated carboxylic acid copolymer, a polycarboxylic acid-modified cellulose derivative, etc.), a drug component is encapsulated with the aqueous solution of the encapsulation agent, the obtained soft capsule is dried and immersed in a solution of an acid of preferably 5-15wt% concentration at &lt;=10 deg.C for about 3min, and the product is washed with water and dried to obtain the objective soft capsule. The amounts of gelatin and the film-forming substance are preferably 60-70% and 10-20%, based on the encapsulation agent, respectively. Preferably, the capsule is incorporated with 10-20% of a polyol such as sorbit, glycerol, etc. as a plasticizer.
PURPOSE:To obtain an amino acid derivative useful as a therapeutic agent for cardiac insufficiency industrially and advantageously by a new method for using a hemiacetal substance prepared by electrically oxidizing a pipecolic acid derivative as an intermediate. CONSTITUTION:A pipecolic acid derivative of formula I (R&lt;3&gt; to R&lt;5&gt; are H, OH, etc.; R&#39;&#39; is a carboxylic acid-protecting group; Z is an acyl or carbamate) is electrically oxidized preferably by a method for using platinum or carbon as an electrode and tetraethylammonium perchlorate as a supporting electrolyte and injecting &gt;=2 Faraday s/mol to the compound of formula I to give a hemiacetal substance of formula II (R&lt;12&gt; forms an aldehyde equivalent with an N atom in the ring) and the objective compound is obtained from the hemiacetal substance. The hemiacetal substance is reacted with a cysteine derivative of formula III (R&lt;2&gt; is H or a carboxylic acid protecting group; R&lt;6&gt; and R&lt;7&gt; are each H, a lower alkyl, etc.) to give a thiazolidine derivative. Then, the compound is deprotected and subjected to ring formation to give an amino acid derivative of formula IV.
PROBLEM TO BE SOLVED: To prepare the granules of a food, a medicine, etc., capable of emphasizing its flavor, fragrance, etc., excellent in texture, capable of being maintained in a good shape from their preparation time to their handling time. SOLUTION: This method for preparing the granules of a food, a medicine, etc., comprises mixing a powdery raw material with the powder of a binder having a melting point of 40-130 deg.C, heating and stirring the mixture at a higher temperature than the melting point of the binder powder or higher, simultaneously spraying the heated and melted products of solid fats containing a solid fat having a melting point of 40-120 deg.C in an amount of &gt;=70% on the heated and stirred mixture, and subsequently cooling the mixture at a lower temperature than the melting point of the binder powder or lower. The powdery raw material includes various kinds of flavor materials and fragrant materials and is used in an amount of 70-95wt.%. The binder powder includes beef tallow and palm oil, and is used in an amount of 4-20wt.%. The solid fats are used in an amount of 1-20wt.%.  The solid fats are the extract fats of a flavor raw component and/or a fragrant raw component, or the heated mixture of a raw material solid fat with the flavor raw material and/or the fragrant raw material. The method for preparing the granules is effective for granulating the powder of a single spice such as pepper, the powder of a mixed spice such as curry powder, etc.
A method can include receiving, at a server, preoperative image data of a patient&#39;s bone, and accessing, at the server, a database of three-dimensional model data. A patient specific three-dimensional model of the patient&#39;s bone can be generated, at the server. A preoperative surgical plan can be generated at the server, which can include comparing aspects of the preoperative surgical plan with predetermined reliability criteria. An interactive user interface for use by a surgeon to review the preoperative surgical plan can be provided, from the server, to a user device. Approval of the preoperative surgical plan can be received, at the server, via the interactive user interface. Postoperative image data of the patient&#39;s bone can be received at the server. A postoperative outcome study report can be generated, at the server, and can include a comparison of the preoperative surgical plan with the postoperative image data.
This invention relates to a novel DNA sequence encoding a bHLH transcription factor in vertebrates, preferably mammals, e.g. in mice or humans, as well as the expressed transcription factor. The invention further relates to vectors containing said DNA sequences and host cells transformed by these vectors. Furthermore, the invention encompasses antibodies specific for the transcription factors as well as the use of the DNA sequences and transcription factors in the diagnosis or therapy of neurodegenerative diseases, e.g. Parkinson&#39;s disease. The present invention further relates to an ex vivo method of producing dopaminergic cells and the therapeutic use of these dopaminergic cells.
Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2&#39;-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such ribonuclease is referred to herein as a dsRNase, wherein &#34;ds&#34; indicates the RNase&#39;s specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.
Generation of competent  Cucumis  sp. embryoids, plantlets and plants (including seeds) from protoplasts, e.g., from cotyledonary , root, leaf or stem tissue, by isolation in enzyme solution followed by cell wall formation, formation of multicellular colonies, formation of minicalli with induction of embryoids, plating of minicalli with maturation of embryoids, and plantlet development from the embryoids in a series of media, CPM-1, -2 and -3, and CTM-4, containing two or more of NAA, ZR, 2,4-D, BAP and GA₃ under defined temperature, time and light conditions. Serial transfer to novel enzyme and  Cucumis  protoplast induction and expression media for defined periods results in cell wall formation, cell division, competent minicalli formation, and induction and expression (maturation) of competent embryoids and plantlets. Transfer to hormone-free development media permits plantlet development, which in turn progress to mature normal, flowering, fruiting plants. The process is applicable to producing encapsulated embryoids from single genotypes or from somatic hybrids as &#34;artificial seeds&#34;. The process applied to increase of F-1 hybrids permits production of &#34;artificial seeds&#34; (encapsulations) in 1/2 to 1/10 the time it would take to produce natural hybrid seeds. Techniques involving p x /c y  somatic hybridization, freeze storage, and post-thawing development are disclosed. Sexual sterility barriers between plants in the genus  Cucumis  preventing genetic transfer of important characteristics are overcome.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellently preventing and improving effect on chapped skin, bettering effect on hair touch, etc. by making the composition include a specific amide derivative. SOLUTION: This composition comprises an amide derivative of the formula (R1 is a 1-39C hydrocarbon; R2 is a 1-12C bifunctional hydrocarbon; R3 is a 2-12C bifunctional hydrocarbon; and R4 is a 2-6C hydroxyalkyl). The composition is obtained by reacting a compound containing two eliminable groups with preferably &gt;=2 equivalent amine by heating preferably at 40-100 deg.C to give an intermediate and reacting the intermediate with a carboxylic acid halide (e.g. a carboxylic acid chloride, etc.), preferably in the presence of a base except the intermediate in a mixed solvent of water and an organic solvent at pH 9-14 to give the amide derivative. The amount of the amide derivative formulated in the composition is preferably 0.001-50 wt.% based on the total composition in the case of an emulsion type external preparation for skin and a skin cosmetic.
The present invention relates to Chinese medicine for treating pain, a preparing process thereof and an application thereof. The Chinese medicine for treating pain is composed of more than 30 kinds of Chinese medicine, such as clore, chiese eaglewood wood, incised notoptetygium rhizome or root, doubleteeth pubesscent angelica root, garden balsam herb, bone extending herb, etc. Two kinds of compound prescription are scientifically prepared, and then, the compound prescription is prepared into series health care products, such as shoe pads, knee pads, waistlines, shoulder pads, etc. By being appressed with skins, medicine potency is exerted by human bodies&#39; temperature to be absorbed. Thus, the Chinese medicine for treating pain can warm the spleen and the stomach for dispelling cold, relaxing ribs, activating collateral flow, relaxing joints, etc. The Chinese medicine for treating pain is an external application product; the Chinese medicine for treating pain not only has no side effect, but also has obvious effect. The Chinese medicine for treating pain is particularly suitable for aged people or population groups with special profession, such as traffic police, etc. The Chinese medicine for treating pain is worth of popularization and application.
When a support request comment is transmitted from an in-hospital terminal (13) of a primary care physician, a distribution server (27) transmits a support request including initial data to each support terminal (TS1, TS2) which a support medical staff uses. A time limit is set on the initial data. After the transmission of the support request, remarks of participants in a medical support consultation and examination images are distributed only to the participants&#39; support terminals. The time limit for the initial data transmitted to the each participant&#39;s support terminal is extended. The time limit for the initial data transmitted to the support terminal of a nonparticipant is not extended. Access to the initial data on the support terminal is disabled when the time limit is reached.
The invention belongs to the field of traditional Chinese medicines and particularly relates to an enema for treating tumor fever and a preparing method thereof. The enema is prepared from following traditional Chinese medicine raw materials by weight: 60-150 parts of gypsum, 8-15 parts of rhizoma anemarrhenae, 8-15 parts of Chinese liquorice, 20-30 parts of dried rehmannia root, 8-15 parts of ophiopogon japonicus, 10-15 parts of radix scutellariae, 20-30 parts of dandelion, 25-35 parts of radix astragali and 25-35 parts of coix seed. The enema and the preparing method are advantageous in that: the traditional Chinese medicines used in the enema meet regulations of the Chinese Pharmacopoeia, and are safe and reliable. The traditional Chinese medicine raw materials are compatible. The enema has functions of clearing heat, drying dampness, purging internal fir, detoxicating, and the like, and has characteristics of low cost, definite curative effects, rapid production of desired effects, capability of not spoiling one&#39;s appetite, simple and convenient administration, capability of being easily acceptable by patients, high curative rate, no side effects, and the like. The enema is particularly suitable for patients with advanced tumor or patients difficult in medicine taking caused by weakness due to chronic disease or patients refusing medicine taking.
This invention is for the treatment of Alzheimer&#39;s disease, Down syndrome, Central (or Peripheral) Nervous Systems&#39; disorders or for the enhancement of memory and central nervous system or peripheral nervous system. In this invention a novel class of Choline derivatives are recommended for the above mentioned indications. These derivatives are the esters of Choline. An example of this class was newly synthesized using Stearic acid. This derivative named Stearyl Choline Cloride or Choline Staearate Chloride or Stearic acid ester of Choline was synthesized and tested in animals. The results are positive.
PROBLEM TO BE SOLVED: To obtain a medicine composition for preventing or treating male sterility, capable of effectively preventing or treating male sterility, by including a sesame meal extract and/or an oyster extract. SOLUTION: This composition contains (A) a sesame meal extract and/or (B) an oyster extract. A sesame meal is mixed with water, heated to &gt;=75 deg.C stirred for &gt;=30 minutes and cooled to 20-70 deg.C to give (i) a sesame meal extract, which is adjusted to proper pH, reacted with a peptidase resistant to an acidic range, heated at &gt;=75 deg.C for &gt;=30 minutes, subjected to a filter press and centrifuged to give (ii) a crude sesame meal essence solution. Then the solution is concentrated, sterilized and dried to give (iii) sesame extract powder. The components (i), (ii) and (iii) are the component A. Crassostreagigas is treated with an enzyme to give (iv) a water-soluble essence, which is concentrated to give (v) a concentrated essence, which is dried to give (vi) oyster essence powder. The components (iv), (v) and (vi) are the component B.
PURPOSE:To obtain a carcinostatic agent comprising an extracted fraction of garlic, especially a fat-soluble fraction as an active ingredient. CONSTITUTION:Any part of garlic plant, preferably bulb part is extracted (preferably extracted at &lt;=40 deg.C for 10-20hr) with a hydrous or anhydrous 1-3C alcohol. The prepared extracted solution is directly extracted with an organic solvent (e.g. chloroform, benzene, acetone or hexane) distributional with water or the extractant alcohol is distilled off and extracted with the solvent, the prepared extracted fraction is optionally washed with water once-several times and concentrated at low temperature under reduced pressure or freeze- dried to give the aimed fraction. The titled carcinostatic agent contains the fraction or a substance derived from the fraction as a main active ingredient. The carcinostatic agent has both suppressing effects on carcinogenesis and antitumor effects in a dose-dependent way and is useful for preventing and treating cancers.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a macromolecular nano complex capable of being stably dispersed in an aqueous solution without being coagulated, and to provide a simple method for producing the complex.  &lt;P&gt;SOLUTION: The macromolecular nano complex is constituted of gelatin or albumin, a protein or a nucleic acid, and a polyvalent metal ion. Preferably, the polyvalent metal ion is a divalent or trivalent metal ion, and is exemplified by a zinc ion. The macromolecular nano complex can easily be produced by mixing a complex constituted of the gelatin or albumin, and the protein or nucleic acid, with an aqueous solution of a polyvalent metal salt. The macromolecular nano complex can stably be dispersed in the aqueous solution because a salt crosslinking or a coordinate bond is formed with the metal ion in the macromolecular nano complex. The strength of the interaction between the gelatin or albumin, and the protein or nucleic acid can be regulated by regulating the concentration of the added metal ion.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide new pure crystal forms of risperidone, and to provide preparation methods thereof.  &lt;P&gt;SOLUTION: The new forms of risperidone, designated Form A, Form B and Form E are provided. Methods for their preparation are also disclosed. The processes for making risperidone are provided. Pharmaceutical compositions containing the new forms of risperidone and methods of using the compositions are also disclosed.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
FIELD: food industry. ^ SUBSTANCE: method deals with production of a smokeless tobacco product (snus) and relates to tobacco industry. The method includes careful selection of tobacco raw material wherein one determines nicotine content by express method immediately after selection. The vegetal raw material is carefully selected and mixed with the selected tobacco raw material. The tobacco raw material and vegetal material mixture is milled, fractionated by way of screen sizing, one selecting the tobacco raw material fraction strained through a sieve with 1ù1 mm size holes. Then one determines nicotine content in the mixture by express method. Then culinary salt water solution is prepared; one pours the solution on the selected fraction and carefully mixes it till a homogeneous mass production. The prepared homogeneous mass is maintained at room temperature during no more than 30 minutes; one measures pH level and adds an acidity regulator in a quantity sufficient for the extract pH to be 7.8 - 8.2. Then one performs pasteurisation by a conventional method and adds a softener to the mixture. One performs cooling and conditioning during one day. One forms smokeless tobacco product from the produced mixture, the product having been prepared in accordance with one of the proposed versions of the invention, and the product is packed by one of the conventional methods. ^ EFFECT: produced smokeless tobacco product satisfies human physiological need for nicotine; it has a specified taste and aroma, contains less toxic agents which reduces the risk of damage to the consumer&#39;s health. ^ 4 cl, 3 tbl